Recent research has underscored the complex influence of varied dietary fibre types on irritable bowel syndrome (IBS), particularly noting their effects on gut transit time and microbiota, notwithstanding certain side effects, such as colonic gas production. A novel trial underpins the differential impact these fibres can have on IBS symptoms and gut microbiota.
The investigation, presented by Dr Jose Maria Remes-Troche (Veracruzana University, Mexico) was a double-blind, placebo-controlled clinical trial (NCT03803319) conducted across Mexico and the United Kingdom [1]. It evaluated the effect of co-administering distinct types of dietary fibres on IBS patients. Participants were given either a placebo, a combined dose of extracted fibres (inulin and psyllium), or native fibres (nopal) twice daily over 8 weeks. The trial’s main objective was to measure the impact of these interventions on the patients’ gut microbiota and IBS symptoms. Secondary objectives included evaluating stool consistency, gut transit times, and microbial metabolites.
Included were 133 patients who were randomised to inulin/psyllium (n=47), nopal (n=44), or placebo (n=42). The results revealed no significant differences in the relief of IBS symptoms assessed by the Global Symptom Question across the 3 groups (P=0.724). However, the incidence and severity of constipation and hard stools were notably reduced in the inulin/psyllium group (4.5%) compared with nopal (15.1%, P=0.026) and placebo (15.6%, P=0.02).
Additionally, the inulin/psyllium group exhibited a decreased Shannon diversity index (4.0) in contrast to both nopal (4.4, P=0.024) and placebo (4.5, P=0.016). In particular, inulin/psyllium resulted in a lower abundance of Ruminococcus (P=0.001), Dorea (P=0.016), and Coprococcus (P=0.011) and higher Bifidobacteria (P=0.055). These changes were not associated with short-chain fatty acid production alterations, suggesting a unique effect on the gut microbiome’s composition.
Overall, the co-administration of inulin and psyllium was shown to mitigate constipation without exacerbating IBS symptoms, despite not leading to overall clinical improvements. These findings suggest the potential for personalised, fibre-based interventions in IBS management, based on individual symptom profiles and microbiota configurations.
- Remes-Troche JM, et al. Fiber co-administration and impact on symptoms, gut transit time and gut microbiome in irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. Lecture 1248, DDW 2023, 6–9 May, Chicago, IL, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
« Mepolizumab shows potential in eosinophilic oesophagitis treatment Next Article
Upadacitinib improves endoscopic outcomes in CD with or without previous biologic failure »
Table of Contents: DDW 2023
Featured articles
Aspirin and NSAIDs could reduce the risk of early-onset colorectal adenomas
Durability of SER-109 clinical response in patients with recurrent C. difficile infection
Online First
Aspirin and NSAIDs could reduce the risk of early-onset colorectal adenomas
Environmental and dietary factors can amplify paediatric IBD risk
Upadacitinib improves endoscopic outcomes in CD with or without previous biologic failure
IBS management: the complex role of dietary fibres
Mepolizumab shows potential in eosinophilic oesophagitis treatment
Novel clinical score for predicting laryngopharyngeal reflux
Durability of SER-109 clinical response in patients with recurrent C. difficile infection
Biologic-naïve patients with CD: real-world data from EVOLVE Expansion
PIPAC technique shows promise for unresectable colorectal peritoneal metastases
Effectiveness of B/F/TAF treatment in HIV/HBV co-infection
Terlipressin promising in hepatorenal syndrome with concomitant alcoholic hepatitis
Linaprazan glurate in the treatment of erosive oesophagitis
Related Articles

Immune cells and microbes: a happy marriage?
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy